Immunomedics, Inc. (Nasdaq: IMMU ), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that subcutaneous administration of veltuzumab, as a single agent, demonstrated promising activity in patients with relapsed immune thrombocytopenia (ITP), even in more heavily treated patients